amsacrine has been researched along with Leucocythaemia in 100 studies
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The side effects and toxicity of the amsacrine-based regimen were similar to that of other antileukemia regimens." | 9.08 | [Phase III clinical trial on domestic amsacrine in patients with acute leukemias]. ( , 1997) |
| "The combination of high-dose cytarabine (ara-C) and amsacrine (m-AMSA) is effective treatment for relapsed adult acute leukemia." | 9.06 | Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. ( Keating, MJ; Nowak, B; Plunkett, W, 1987) |
| "Amsacrine and high-dose cytarabine (HiDAc), when administered as single agents, are effective treatment of acute leukemia." | 9.06 | A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Feldman, E; Mehta, R; Mittelman, A; Rieber, E; Sullivan, P; Weinstein, P, 1987) |
| "This study explores the suppression mechanism of amsacrine (4-(9-Acridinylamino)-N-(methanesulfonyl)-m-anisidine hydrochloride) on matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in human leukemia cells." | 7.80 | Amsacrine suppresses matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in human leukemia cells. ( Chang, LS; Chen, YJ; Chien, JH; Liu, WH, 2014) |
| "Amsacrine (AMSA) was a high effective medicine of acute leukemia treatment." | 7.69 | [Venous protection of acute leukemia treatment with amsacrine]. ( Hong, J; Ma, XJ; Xiang, YM, 1996) |
| "The role of amsacrine in inducing remission in patients with cardiac disease and acute leukemia was evaluated." | 7.68 | Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Chun, HG; Cook, P; Feldman, EJ; Marboe, C; Mehta, R; Mittelman, A; Puccio, C, 1991) |
| "The antileukemia drug amsacrine and seven analogues were tested for in vitro activity against five multidrug-resistant human leukemia cell sublines (two derived from each of two Jurkat parent lines and one from the K562 line) and the corresponding parent lines (Jurkat, K562, and P388 leukemia)." | 7.68 | Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues. ( Baguley, BC; Finlay, GJ; Judd, W; Snow, K, 1990) |
| "The characterization of type II topoisomerases from amsacrine-sensitive (HL-60) and amsacrine-resistant (HL-60/AMSA) human leukemia cells was extended." | 7.68 | Further characterization of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target. ( Altschuler, E; Hinds, M; Kim, P; Mayes, J; Soares, L; Zwelling, LA, 1993) |
| "Twenty-two evaluable adult patients with relapsed, acute nonlymphocytic leukemia (ANLL) were treated with the combination of amsacrine (m-AMSA) and 5-azacytidine (AZA) as part of an Eastern Cooperative Oncology Group (ECOG) pilot study to evaluate efficacy and toxicity." | 7.67 | Amsacrine [4'-(9-acridinylamino)-methanesulfon-m-anisidide] (m-AMSA) and 5-azacytidine (AZA) for remission reinduction in patients with relapsed adult acute nonlymphocytic leukemia. An ECOG pilot study. Eastern Cooperative Oncology Group. ( Glick, JH; Kahn, SB; Knospe, WH; Soojian, M; Spiers, A, 1987) |
| "Fourteen patients with refractory acute non-lymphocytic leukemia were entered into a dose-seeking trial of combination therapy with etoposide and amsacrine given daily for five consecutive days." | 7.67 | Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia. ( Hinemann, V; Hoagland, HC; Kovach, JS; Letendre, L, 1985) |
| "Amsacrine (AMSA) has been shown to be an effective therapeutic agent in the treatment of adult acute nonlymphocytic leukemia (ANLL)." | 7.67 | High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study. ( Bennett, JM; Cassileth, PA; Glick, JH; Lyman, GH; Oken, MM, 1984) |
| "The authors report a case of focal myocardial necrosis, presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug, amsacrine, in a patient without coronary artery disease." | 7.67 | Acute myocardial necrosis during administration of amsacrine. ( Burns, CP; Lindpaintner, K; Lindpaintner, LS; Wentworth, M, 1986) |
| "In order to test the toxicity and efficacy of intensive postremission therapy with high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide in adults with acute nonlymphocytic leukemia (ANL), 100 adults (ages 19 to 75) with previously untreated ANL were entered into a study using six sequential cycles of chemotherapy." | 7.67 | Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide. ( Amos, D; Appelbaum, FR; Goldberg, RS; Livingston, RB; Mortimer, J; Tallman, MS; Thomas, ED; Weiden, PL, 1987) |
| "We varied the number of doses of high-dose cytarabine (3 g/m2) given to patients with acute leukemia in relapse who were receiving therapeutic doses of amsacrine (600 mg/m2/course)." | 7.67 | Treatment of acute leukemia with amsacrine and high-dose cytarabine. ( Ahmed, T; Arlin, ZA; Friedland, M; Gaddipati, J; Mittelman, A; Rieber, E, 1985) |
| "Thirteen patients (7 male, 9 female) aged 22-71 years (means = 55 years) with acute non-lymphocytic leukemia and contraindications for anthracyclin therapy were treated with combined chemotherapy using m-amsacrine primarily or in relapse." | 7.67 | Combined chemotherapy with m-amsacrine in high-risk patients with acute non-lymphocytic leukemia. ( Hiddemann, W; Kreutzmann, H; Maschmeyer, G; Wendt, F, 1987) |
| "Twenty-six adults with refractory leukemia were treated with amsacrine gluconate, a new formulation." | 7.66 | Phase II study of amsacrine gluconate in refractory leukemia. ( Grillo-Lopez, AJ; Omura, GA; Vogler, WR; Winton, EF; Zuckerman, KS, 1983) |
| " The side effects and toxicity of the amsacrine-based regimen were similar to that of other antileukemia regimens." | 5.08 | [Phase III clinical trial on domestic amsacrine in patients with acute leukemias]. ( , 1997) |
| "The combination of high-dose cytarabine (ara-C) and amsacrine (m-AMSA) is effective treatment for relapsed adult acute leukemia." | 5.06 | Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. ( Keating, MJ; Nowak, B; Plunkett, W, 1987) |
| "This clinical trial (DT7995) was designed to evaluate amsacrine (AMSA) plus cytosine arabinoside (ara-C), vincristine, and prednisone (OAP) therapy in previously untreated patients with adult acute leukemia and to investigate a new strategy for assignment of patients to treatment using estimated probabilities of complete remission (PPR) based on six prognostic factors." | 5.06 | A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. ( Estey, EH; Freireich, EJ; Gehan, EA; Kantarjian, HM; Keating, MJ; McCredie, KB; Smith, TL; Walters, RS, 1987) |
| "Amsacrine and high-dose cytarabine (HiDAc), when administered as single agents, are effective treatment of acute leukemia." | 5.06 | A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Feldman, E; Mehta, R; Mittelman, A; Rieber, E; Sullivan, P; Weinstein, P, 1987) |
| "Amsacrine is an antileukemia drug being widely used in North America, Europe, Australia, and New Zealand." | 5.06 | Amsacrine-associated cardiotoxicity: an analysis of 82 cases. ( Grillo-López, AJ; Hess, F; Marsoni, S; Posada, JG; Ross, BJ; Weiss, RB, 1986) |
| "This study explores the suppression mechanism of amsacrine (4-(9-Acridinylamino)-N-(methanesulfonyl)-m-anisidine hydrochloride) on matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in human leukemia cells." | 3.80 | Amsacrine suppresses matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in human leukemia cells. ( Chang, LS; Chen, YJ; Chien, JH; Liu, WH, 2014) |
| " The single-arm trial evaluated amsacrine plus cytosine arabinoside, vincristine, and prednisone (a combination abbreviated as OAP) for adult acute leukemia, when standard treatment was adriamycin plus OAP." | 3.75 | Treatment-subgroup interaction: an example from a published, phase II clinical trial. ( Behrendt, CE; Gehan, EA, 2009) |
| "Amsacrine (AMSA) was a high effective medicine of acute leukemia treatment." | 3.69 | [Venous protection of acute leukemia treatment with amsacrine]. ( Hong, J; Ma, XJ; Xiang, YM, 1996) |
| "The antileukemia drug amsacrine and seven analogues were tested for in vitro activity against five multidrug-resistant human leukemia cell sublines (two derived from each of two Jurkat parent lines and one from the K562 line) and the corresponding parent lines (Jurkat, K562, and P388 leukemia)." | 3.68 | Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues. ( Baguley, BC; Finlay, GJ; Judd, W; Snow, K, 1990) |
| "The role of amsacrine in inducing remission in patients with cardiac disease and acute leukemia was evaluated." | 3.68 | Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Chun, HG; Cook, P; Feldman, EJ; Marboe, C; Mehta, R; Mittelman, A; Puccio, C, 1991) |
| "The coumermycin antibiotic novobiocin, which interacts with the nuclear enzyme topoisomerase II, produced supra-additive toxicity to WEHI-3B D+ leukemia cells at clinically achievable concentrations, when combined with teniposide (VM-26) or etoposide (VP-16)." | 3.68 | Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26). ( Lorico, A; Rappa, G; Sartorelli, AC, 1992) |
| "The characterization of type II topoisomerases from amsacrine-sensitive (HL-60) and amsacrine-resistant (HL-60/AMSA) human leukemia cells was extended." | 3.68 | Further characterization of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target. ( Altschuler, E; Hinds, M; Kim, P; Mayes, J; Soares, L; Zwelling, LA, 1993) |
| "Twenty-two evaluable adult patients with relapsed, acute nonlymphocytic leukemia (ANLL) were treated with the combination of amsacrine (m-AMSA) and 5-azacytidine (AZA) as part of an Eastern Cooperative Oncology Group (ECOG) pilot study to evaluate efficacy and toxicity." | 3.67 | Amsacrine [4'-(9-acridinylamino)-methanesulfon-m-anisidide] (m-AMSA) and 5-azacytidine (AZA) for remission reinduction in patients with relapsed adult acute nonlymphocytic leukemia. An ECOG pilot study. Eastern Cooperative Oncology Group. ( Glick, JH; Kahn, SB; Knospe, WH; Soojian, M; Spiers, A, 1987) |
| "The ability of a noncytotoxic dose of ara-C to modulate the amount of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA)- or etoposide-induced topoisomerase II-mediated DNA cleavage and cytotoxicity was examined in m-AMSA-sensitive and -resistant HL-60 human leukemia cells." | 3.67 | Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human le ( Andersson, BS; Bakic, M; Beran, M; Chan, D; Estey, E; Ricketts, L; Silberman, L; Zwelling, LA, 1987) |
| "Thirteen patients (7 male, 9 female) aged 22-71 years (means = 55 years) with acute non-lymphocytic leukemia and contraindications for anthracyclin therapy were treated with combined chemotherapy using m-amsacrine primarily or in relapse." | 3.67 | Combined chemotherapy with m-amsacrine in high-risk patients with acute non-lymphocytic leukemia. ( Hiddemann, W; Kreutzmann, H; Maschmeyer, G; Wendt, F, 1987) |
| "The ECG effect of amsacrine (m-AMSA) was evaluated in 12 consecutive patients with leukemia." | 3.67 | Acute electrocardiographic changes induced by amsacrine. ( Hasin, Y; Shinar, E, 1984) |
| "The authors report a case of focal myocardial necrosis, presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug, amsacrine, in a patient without coronary artery disease." | 3.67 | Acute myocardial necrosis during administration of amsacrine. ( Burns, CP; Lindpaintner, K; Lindpaintner, LS; Wentworth, M, 1986) |
| "In order to test the toxicity and efficacy of intensive postremission therapy with high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide in adults with acute nonlymphocytic leukemia (ANL), 100 adults (ages 19 to 75) with previously untreated ANL were entered into a study using six sequential cycles of chemotherapy." | 3.67 | Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide. ( Amos, D; Appelbaum, FR; Goldberg, RS; Livingston, RB; Mortimer, J; Tallman, MS; Thomas, ED; Weiden, PL, 1987) |
| "Thirty-five adults with acute nonlymphocytic leukemia who were in complete remission after initial induction therapy received a single course of high-dose cytarabine and amsacrine as consolidation therapy." | 3.67 | Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia. ( Begg, CB; Bennett, JM; Burkart, PT; Cassileth, PA; Knospe, WH; Mazza, JJ; Oken, MM; Scharfman, W; Silber, R; Spiers, A, 1987) |
| "Fourteen patients with refractory acute non-lymphocytic leukemia were entered into a dose-seeking trial of combination therapy with etoposide and amsacrine given daily for five consecutive days." | 3.67 | Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia. ( Hinemann, V; Hoagland, HC; Kovach, JS; Letendre, L, 1985) |
| "Amsacrine (AMSA) has been shown to be an effective therapeutic agent in the treatment of adult acute nonlymphocytic leukemia (ANLL)." | 3.67 | High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study. ( Bennett, JM; Cassileth, PA; Glick, JH; Lyman, GH; Oken, MM, 1984) |
| "We varied the number of doses of high-dose cytarabine (3 g/m2) given to patients with acute leukemia in relapse who were receiving therapeutic doses of amsacrine (600 mg/m2/course)." | 3.67 | Treatment of acute leukemia with amsacrine and high-dose cytarabine. ( Ahmed, T; Arlin, ZA; Friedland, M; Gaddipati, J; Mittelman, A; Rieber, E, 1985) |
| "Among new drugs being studied currently, AMSA and mitoxantrone have shown significant usefulness against acute non-lymphocytic leukemia in adults." | 3.67 | [A new drug and current strategy in the treatment of acute non-lymphocytic leukemia in adults]. ( Ogawa, M, 1986) |
| "Twenty-six adults with refractory leukemia were treated with amsacrine gluconate, a new formulation." | 3.66 | Phase II study of amsacrine gluconate in refractory leukemia. ( Grillo-Lopez, AJ; Omura, GA; Vogler, WR; Winton, EF; Zuckerman, KS, 1983) |
| "m-AMSA is a new drug in the National Cancer Institute Drug Development Program." | 2.65 | m-AMSA: an exciting new drug in the National Cancer Institute Drug Development Program. ( Charles, LM; Macdonald, JS; Weiss, RB, 1980) |
| "Bacterial or fungal infections (considered life-threatening or fatal) occurred in 17 children with ALL and in 7 with ANLL." | 2.65 | Evaluation of AMSA in children with acute leukemia. A Pediatric Oncology Group study. ( Civin, CI; Frankel, LS; Krischer, J; Land, VJ; Mahoney, DH; Ragab, AH, 1984) |
| "The sinusitis was successfully treated with AmBisome, and surgical debridement." | 1.33 | Zygomycosis in the immunocompromised patient: a case report. ( Aoun, M; Beguin, H; Georgala, A; Husson, M; Meuleman, N; Nolard, N; Vekemans, M, 2006) |
| " push in a dosage of 150 mg/m2 for 5 days." | 1.27 | 4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia. ( Brodsky, I; Bulova, S; Conroy, JF; Kahn, SB; Lebedda, J; Sklaroff, R, 1983) |
| "A pharmacokinetic study was performed in 13 adult patients with acute nonlymphoblastic leukemia to compare two formulations of 4'-(9-acridinylamino)-methanesulphone-m-ansidide (AMSA): the original formulation, AMSA-NCL, and a water-soluble lyophilized formulation, AMSA-lactate (Bristol Myers, Syracuse, N." | 1.27 | Comparison of the pharmacokinetics of AMSA and AMSA-lactate in patients with acute nonlymphoblastic leukemia. ( Farmen, RH; Franks, CR; Liliemark, JO; Paul, CY; Peterson, CO; Uytdenhoef, M, 1987) |
| "Hyperbilirubinemia was seen in 25% of the patients treated." | 1.26 | Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia. ( Arlin, ZA; Clarkson, BD; Gee, TS; Howard, J; Kempin, SJ; Sklaroff, RB; Young, CW, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 71 (71.00) | 18.7374 |
| 1990's | 22 (22.00) | 18.2507 |
| 2000's | 5 (5.00) | 29.6817 |
| 2010's | 1 (1.00) | 24.3611 |
| 2020's | 1 (1.00) | 2.80 |
| Authors | Studies |
|---|---|
| Spicer, JA | 1 |
| Gamage, SA | 1 |
| Atwell, GJ | 1 |
| Finlay, GJ | 4 |
| Baguley, BC | 7 |
| Denny, WA | 1 |
| Kolb, HJ | 1 |
| Schmid, C | 1 |
| Liu, WH | 1 |
| Chen, YJ | 1 |
| Chien, JH | 1 |
| Chang, LS | 1 |
| Behrendt, CE | 1 |
| Gehan, EA | 2 |
| Tauro, S | 1 |
| Shankaranarayana, P | 1 |
| Nitu-Whalley, IC | 1 |
| Duncan, N | 1 |
| Begum, G | 1 |
| Craig, JI | 1 |
| Marcus, RE | 1 |
| Craddock, CF | 1 |
| Mahendra, P | 1 |
| Boutonnat, J | 1 |
| Faussat, AM | 1 |
| Marie, JP | 1 |
| Bignon, J | 1 |
| Wdzieczak-Bakala, J | 1 |
| Barbier, M | 1 |
| Thierry, J | 1 |
| Ronot, X | 1 |
| Colle, PE | 1 |
| Georgala, A | 1 |
| Vekemans, M | 1 |
| Husson, M | 1 |
| Meuleman, N | 1 |
| Beguin, H | 1 |
| Nolard, N | 1 |
| Aoun, M | 1 |
| Carella, AM | 1 |
| Santini, G | 1 |
| Marmont, AM | 1 |
| Miller, LP | 1 |
| Miller, DR | 2 |
| Tan, CT | 2 |
| Kahn, SB | 2 |
| Sklaroff, R | 1 |
| Lebedda, J | 1 |
| Conroy, JF | 1 |
| Bulova, S | 1 |
| Brodsky, I | 1 |
| Gahrton, G | 1 |
| Hines, JD | 3 |
| Oken, MM | 5 |
| Mazza, JJ | 4 |
| Keller, AM | 1 |
| Streeter, RR | 1 |
| Glick, JH | 3 |
| Arlin, ZA | 9 |
| Carter, SK | 1 |
| Naparstek, E | 1 |
| Shinar, E | 2 |
| Polliack, A | 1 |
| Cassileth, PA | 2 |
| Lyman, GH | 1 |
| Bennett, JM | 4 |
| Omura, GA | 1 |
| Winton, EF | 1 |
| Vogler, WR | 1 |
| Zuckerman, KS | 1 |
| Grillo-Lopez, AJ | 2 |
| Estey, EH | 2 |
| Keating, MJ | 5 |
| Smith, TL | 2 |
| McCredie, KB | 7 |
| Legha, SS | 4 |
| Walters, RS | 2 |
| Bodey, GP | 4 |
| Freireich, EJ | 4 |
| Krischer, J | 1 |
| Land, VJ | 1 |
| Civin, CI | 1 |
| Ragab, AH | 1 |
| Mahoney, DH | 1 |
| Frankel, LS | 1 |
| Case, DC | 1 |
| Hasin, Y | 1 |
| Mittelman, A | 4 |
| Zander, AR | 1 |
| Vellekoop, L | 1 |
| Dicke, KA | 1 |
| Spitzer, G | 1 |
| Verma, D | 1 |
| Check, WA | 1 |
| Goldsmith, MA | 1 |
| Bhardwaj, S | 1 |
| Ohnuma, T | 1 |
| Greenspan, EM | 1 |
| Holland, JF | 1 |
| Flomenberg, N | 1 |
| Gee, TS | 2 |
| Kempin, SJ | 2 |
| Dellaquila, C | 1 |
| Mertelsmann, R | 1 |
| Straus, DJ | 1 |
| Young, CW | 2 |
| Clarkson, BD | 2 |
| Hancock, C | 1 |
| Steinherz, PG | 1 |
| Steinherz, LJ | 1 |
| Sorell, M | 1 |
| Chan, KW | 1 |
| Mondora, A | 1 |
| Mahal, PS | 1 |
| Valdivieso, M | 1 |
| Luna, M | 1 |
| Benjamin, RS | 1 |
| Ahmann, FR | 1 |
| Meyskens, FL | 1 |
| Moon, TE | 1 |
| Durie, BG | 1 |
| Salmon, SE | 1 |
| Horikoshi, N | 1 |
| Ogawa, M | 2 |
| Inagaki, J | 1 |
| Ezaki, K | 1 |
| Inoue, K | 1 |
| Okabe, K | 1 |
| Nagata, T | 1 |
| Aiba, K | 1 |
| Domyo, M | 1 |
| Sklaroff, RB | 1 |
| Howard, J | 1 |
| Fanucchi, MP | 1 |
| Macdonald, JS | 2 |
| Marsoni, S | 2 |
| Bruno, S | 1 |
| Poster, D | 1 |
| Weiss, RB | 2 |
| Charles, LM | 1 |
| Lawrence, HJ | 1 |
| Ries, CA | 1 |
| Reynolds, RD | 1 |
| Lewis, JP | 1 |
| Koretz, MM | 1 |
| Torti, FM | 1 |
| Boege, F | 2 |
| Biersack, H | 2 |
| Meyer, P | 2 |
| Ellis, AL | 1 |
| Nowak, B | 2 |
| Plunkett, W | 3 |
| Zwelling, LA | 7 |
| Mayes, J | 3 |
| Hinds, M | 3 |
| Soares, L | 1 |
| Altschuler, E | 3 |
| Kim, P | 1 |
| Lyytikäinen, O | 1 |
| Elonen, E | 1 |
| Lautenschlager, I | 1 |
| Jokipii, A | 1 |
| Tiittanen, L | 1 |
| Ruutu, P | 1 |
| Riou, JF | 1 |
| Davey, RA | 1 |
| Su, GM | 1 |
| Hargrave, RM | 1 |
| Harvie, RM | 1 |
| Davey, MW | 1 |
| Ma, XJ | 1 |
| Xiang, YM | 1 |
| Hong, J | 1 |
| Laurençot, CM | 1 |
| Scheffer, GL | 1 |
| Scheper, RJ | 1 |
| Shoemaker, RH | 1 |
| Laroche-Clary, A | 1 |
| Larrue, A | 1 |
| Robert, J | 1 |
| Mitchell, MJ | 1 |
| Satitpunwaycha, P | 1 |
| Gieseler, F | 1 |
| Granzen, B | 1 |
| Graves, DE | 1 |
| Danks, MK | 2 |
| Beck, WT | 2 |
| Rappa, G | 1 |
| Lorico, A | 1 |
| Sartorelli, AC | 1 |
| Ehninger, G | 1 |
| Proksch, B | 1 |
| Wanner, T | 1 |
| Schuler, U | 1 |
| Busch, FW | 1 |
| Schmidt, H | 1 |
| Schleyer, E | 1 |
| Jaschonek, K | 1 |
| Hiddemann, W | 2 |
| Chan, D | 3 |
| Richel, DJ | 1 |
| Colly, LP | 1 |
| Kluin-Nelemans, JC | 1 |
| Willemze, R | 2 |
| Feldman, EJ | 1 |
| Ahmed, T | 3 |
| Puccio, C | 1 |
| Chun, HG | 1 |
| Cook, P | 1 |
| Baskind, P | 2 |
| Marboe, C | 1 |
| Mehta, R | 3 |
| Snow, K | 1 |
| Judd, W | 1 |
| Fernandes, DJ | 1 |
| Marit, G | 1 |
| Cony, P | 1 |
| Duclos, F | 1 |
| Puntous, M | 1 |
| Broustet, A | 1 |
| Reiffers, J | 1 |
| Cunningham, M | 1 |
| Hanauske, AR | 2 |
| Hanauske, U | 1 |
| Von Hoff, DD | 2 |
| Spiers, A | 2 |
| Knospe, WH | 2 |
| Soojian, M | 1 |
| Brons, PP | 1 |
| Wessels, JM | 1 |
| Linssen, PC | 1 |
| Haanen, C | 2 |
| Speth, PA | 1 |
| Jehn, U | 3 |
| Estey, E | 2 |
| Bakic, M | 2 |
| Silberman, L | 2 |
| Andersson, BS | 3 |
| Beran, M | 3 |
| Ricketts, L | 1 |
| Maschmeyer, G | 1 |
| Kreutzmann, H | 1 |
| Wendt, F | 1 |
| Adelstein, DJ | 2 |
| Keller, A | 2 |
| O'Connell, MJ | 2 |
| Petti, MC | 1 |
| Avvisati, G | 1 |
| Tafuri, A | 1 |
| Meloni, G | 1 |
| Amadori, S | 1 |
| Mandelli, F | 1 |
| Liang, R | 1 |
| Chan, TK | 1 |
| Todd, D | 1 |
| Dhaliwal, HS | 1 |
| Shannon, MS | 1 |
| Barnett, MJ | 1 |
| Prentice, HG | 1 |
| Bragman, K | 1 |
| Malpas, JS | 1 |
| Lister, TA | 1 |
| Posada, JG | 1 |
| Hess, F | 1 |
| Ross, BJ | 1 |
| Feldman, E | 2 |
| Weinstein, P | 1 |
| Rieber, E | 2 |
| Sullivan, P | 2 |
| Van Mouwerik, TJ | 1 |
| Caines, PM | 1 |
| Ballentine, R | 1 |
| Kantarjian, HM | 1 |
| Arlin, Z | 1 |
| Pucillo, A | 1 |
| Tallman, MS | 1 |
| Appelbaum, FR | 1 |
| Amos, D | 1 |
| Goldberg, RS | 1 |
| Livingston, RB | 1 |
| Mortimer, J | 1 |
| Weiden, PL | 1 |
| Thomas, ED | 1 |
| Stuckey, SE | 1 |
| Mavligit, GM | 1 |
| Schiffer, CA | 1 |
| Davis, RB | 1 |
| Mayer, RJ | 1 |
| Peterson, BA | 1 |
| Lee, EJ | 1 |
| Dekker, AW | 1 |
| Punt, K | 1 |
| Verdonck, LF | 1 |
| Paul, CY | 1 |
| Liliemark, JO | 1 |
| Farmen, RH | 1 |
| Franks, CR | 1 |
| Uytdenhoef, M | 1 |
| Peterson, CO | 1 |
| Lindpaintner, K | 1 |
| Lindpaintner, LS | 1 |
| Wentworth, M | 1 |
| Burns, CP | 1 |
| Abrams, RA | 1 |
| Hanson, G | 1 |
| Hansen, RM | 1 |
| Anderson, T | 1 |
| Odaimi, M | 1 |
| Wilson, WR | 1 |
| Keating, M | 1 |
| Begg, CB | 1 |
| Silber, R | 1 |
| Burkart, PT | 1 |
| Scharfman, W | 1 |
| Letendre, L | 1 |
| Hinemann, V | 1 |
| Hoagland, HC | 1 |
| Kovach, JS | 1 |
| Gaddipati, J | 1 |
| Friedland, M | 1 |
| Zittoun, R | 2 |
| Bury, J | 1 |
| Stryckmans, P | 1 |
| Lowenberg, B | 1 |
| Peetermans, M | 1 |
| Rozendaal, KY | 1 |
| Kerkhofs, M | 1 |
| Louie, AC | 1 |
| Issell, BF | 1 |
| Edelstein, M | 1 |
| Valeriote, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia[NCT01822015] | Early Phase 1 | 55 participants (Actual) | Interventional | 2013-03-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for amsacrine and Leucocythaemia
| Article | Year |
|---|---|
The FLAMSA concept-past and future.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Foreca | 2020 |
Treatment of acute leukemia--advances in chemotherapy, immunotherapy, and bone marrow transplantation.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aminoacridines; Amsacrine; Anthraquinone | 1983 |
Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia.
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical T | 1983 |
New cytotoxic drugs for breast cancer and their clinical evaluation.
Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as | 1980 |
Nonhematologic toxicities of selected chemotherapeutic agents used in the treatment of adult leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; | 1990 |
The human tumor cloning assay in cancer research and therapy: a review with clinical correlations.
Topics: Aminoacridines; Amsacrine; Animals; Anthracenes; Antineoplastic Agents; Blood Physiological Phenomen | 1985 |
Topoisomerase II as a target of antileukemia drugs: a review of controversial areas.
Topics: Amsacrine; Antineoplastic Agents; DNA; DNA Topoisomerases, Type II; Humans; Leukemia | 1989 |
New drugs in the treatment of acute and chronic leukaemia: current role of mAMSA.
Topics: Acute Disease; Adult; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothera | 1989 |
New strategies in the management of acute leukemias.
Topics: Acute Disease; Amsacrine; Aneuploidy; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 1987 |
Amsacrine (AMSA)--a clinical review.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 1985 |
Cytosine arabinoside in experimental combination therapy.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosyl | 1985 |
m-AMSA: a review of clinical data.
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Drug Evalu | 1985 |
Clinical correlations with the human tumor cloning assay.
Topics: Aminoacridines; Amsacrine; Anthracenes; Breast Neoplasms; Clinical Trials as Topic; Clone Cells; Cul | 1985 |
14 trials available for amsacrine and Leucocythaemia
| Article | Year |
|---|---|
[Phase III clinical trial on domestic amsacrine in patients with acute leukemias].
Topics: Adolescent; Adult; Aged; Amsacrine; Child; Child, Preschool; Female; Humans; Leukemia; Male; Middle | 1997 |
Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia.
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical T | 1983 |
New cytotoxic drugs for breast cancer and their clinical evaluation.
Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as | 1980 |
Evaluation of AMSA in children with acute leukemia. A Pediatric Oncology Group study.
Topics: Acute Disease; Adolescent; Aminoacridines; Amsacrine; Antineoplastic Agents; Child; Drug Administrat | 1984 |
High-dose AMSA and autologous bone marrow transplantation in relapsed acute leukemia.
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Bone Marrow Transplantation; | 1982 |
m-AMSA: an exciting new drug in the National Cancer Institute Drug Development Program.
Topics: Acute Disease; Aminoacridines; Amsacrine; Breast Neoplasms; Clinical Trials as Topic; Dose-Response | 1980 |
AMSA--a promising new agent in refractory acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Child; Cli | 1982 |
Amsacrine-associated cardiotoxicity: an analysis of 82 cases.
Topics: Adolescent; Aminoacridines; Amsacrine; Antineoplastic Agents; Arrhythmias, Cardiac; Cardiomyopathies | 1986 |
A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; B | 1987 |
Amsacrine evaluation.
Topics: Adult; Amsacrine; Child; Clinical Trials as Topic; Humans; Kinetics; Leukemia; Neoplasms | 1987 |
A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; C | 1987 |
Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Arabinofurano | 1987 |
Amsacrine (AMSA)--a clinical review.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 1985 |
Clinical correlations with the human tumor cloning assay.
Topics: Aminoacridines; Amsacrine; Anthracenes; Breast Neoplasms; Clinical Trials as Topic; Clone Cells; Cul | 1985 |
77 other studies available for amsacrine and Leucocythaemia
| Article | Year |
|---|---|
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
Topics: Acridines; Animals; Antineoplastic Agents; Cell Division; Colonic Neoplasms; Enzyme Inhibitors; Leuk | 1997 |
Amsacrine suppresses matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in human leukemia cells.
Topics: Amsacrine; Down-Regulation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Leuke | 2014 |
Treatment-subgroup interaction: an example from a published, phase II clinical trial.
Topics: Acute Disease; Adult; Amsacrine; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocol | 2009 |
Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; He | 2003 |
Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.
Topics: Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Br | 2005 |
Zygomycosis in the immunocompromised patient: a case report.
Topics: Absidia; Acute Disease; Aerosols; Amphotericin B; Amsacrine; Antibiotic Prophylaxis; Antifungal Agen | 2006 |
Amsacrine and 5-azacytidine in acute non lymphatic leukaemia (ANLL).
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Azacitidine; Humans; Leukemia | 1982 |
Combination chemotherapy with amsacrine (AMSA) and cyclocytidine in refractory childhood leukemia: preliminary observations of a phase II study.
Topics: Adolescent; Aminoacridines; Amsacrine; Ancitabine; Antineoplastic Agents; Child; Child, Preschool; C | 1983 |
4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia.
Topics: Acute Disease; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Azacitidine; Drug Ther | 1983 |
High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Combined Chemother | 1984 |
Acridinyl anisidide (m-AMSA) therapy in 11 patients with refractory acute leukemia.
Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Bone Marrow; Cytarabine; Drug Evaluation; Drug Therapy | 1984 |
High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study.
Topics: Acute Disease; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Drug Administration Sc | 1984 |
Phase II study of amsacrine gluconate in refractory leukemia.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Drug Evaluation; Female; Gluconates; Humans; Lactates; Leuke | 1983 |
Prediction of complete remission in patients with refractory acute leukemia treated with AMSA.
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Female; Humans; Leukemia; Leukemia, Lymphoid; Leuke | 1984 |
m-AMSA: phase II trial in advanced lymphoma and leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Bone Marro | 1984 |
Acute electrocardiographic changes induced by amsacrine.
Topics: Acute Disease; Adolescent; Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic C | 1984 |
AMSA-induced seizures in patients with hypokalemia.
Topics: Aminoacridines; Amsacrine; Female; Humans; Hypokalemia; Leukemia; Middle Aged; Seizures | 1983 |
Laboratory-designed drug used against leukemia.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Drug Therapy, Combination; Humans; Leukemia | 1980 |
Phase I study of m-AMSA in patients with solid tumors and leukemias.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Chemical and Drug Induced Liver I | 1980 |
Treatment of acute leukemia in relapse with 4'(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Chemical a | 1981 |
Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.
Topics: Acute Disease; Adolescent; Aminoacridines; Amsacrine; Antineoplastic Agents; Child; Child, Preschool | 1982 |
AMSA toxicity in patients with abnormal liver function.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Dose-Response Relationship, Drug; Hum | 1981 |
In vitro chemosensitivities of human tumor stem cells to the Phase II drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and prospective in vivo correlations.
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Cells, Cultured; Drug Evaluation; Female; Genital | 1982 |
[Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)].
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Fe | 1982 |
Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia.
Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Drug Administration Schedule; Drug Evaluation; Humans; | 1980 |
Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults.
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Agents; Dose-Response Relationship, Drug; H | 1982 |
Successful treatment of a patient with acute nonlymphoblastic leukemia (ANLL) and anthracycline cardiomyopathy with 4' (9-acridinylamino) methanesulfon-m-anisidide (AMSA).
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; | 1982 |
Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.
Topics: Adenosine Deaminase Inhibitors; Aminoacridines; Amsacrine; Anthracenes; Antineoplastic Agents; Cofor | 1982 |
Drug-sensitivity and DNA-binding of a subform of topoisomerase II alpha in resistant human HL-60 cells.
Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; DNA Topoisomerases, Type II; DNA-Binding Prote | 1994 |
Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Topics: Amsacrine; Antineoplastic Agents; Camptothecin; DNA Probes; DNA Topoisomerases, Type I; DNA Topoisom | 1994 |
Further characterization of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target.
Topics: Adenosine Triphosphate; Amsacrine; Anions; Catalysis; DNA; DNA Damage; DNA Topoisomerases, Type II; | 1993 |
Pneumocystis carinii pneumonia in adults with acute leukaemia: is there a need for primary chemoprophylaxis?
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmus | 1996 |
From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.
Topics: Acridines; Amsacrine; Antineoplastic Agents; DNA; DNA Damage; DNA Topoisomerases, Type I; DNA Topois | 1996 |
The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro.
Topics: Acridines; Amsacrine; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1 | 1997 |
[Venous protection of acute leukemia treatment with amsacrine].
Topics: Acute Disease; Amsacrine; Antineoplastic Agents; Fluid Therapy; Humans; Leukemia; Phlebitis | 1996 |
Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines.
Topics: Amsacrine; Antineoplastic Agents; ATP-Binding Cassette Transporters; Cell Nucleus; Cisplatin; Coloni | 1997 |
Down-regulation of bcr-abl and bcl-x(L) expression in a leukemia cell line and its doxorubicin-resistant variant by topoisomerase II inhibitors.
Topics: Amsacrine; Antineoplastic Agents; Apoptosis; bcl-X Protein; Chromatography, High Pressure Liquid; Do | 2000 |
Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
Topics: Amsacrine; Benzenesulfonamides; Carbamates; Computer Simulation; DNA Topoisomerases, Type I; DNA Top | 1992 |
The measurement of nuclear topoisomerase II inhibition in vitro: a possible tool for detecting resistance on a subcellular level in haematopoietic malignancies.
Topics: Amsacrine; Antineoplastic Agents; Cell Nucleus; Drug Resistance; Etoposide; Humans; In Vitro Techniq | 1992 |
Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.
Topics: Amsacrine; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Cell Division; DN | 1992 |
Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
Topics: Adenocarcinoma; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; DNA; DNA T | 1992 |
Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide.
Topics: Acute Disease; Adult; Aged; Amsacrine; Arabinofuranosylcytosine Triphosphate; Cytarabine; Drug Inter | 1992 |
The effect of staurosporine on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
Topics: Alkaloids; Amsacrine; Cell Line; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Dose-Respon | 1991 |
The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.
Topics: Acute Disease; Adult; Amsacrine; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemot | 1991 |
Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia.
Topics: Amsacrine; Cardiac Output, Low; Cytarabine; Drug Therapy, Combination; Humans; Leukemia; Leukemia, M | 1991 |
Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues.
Topics: Amsacrine; Drug Resistance; Humans; Leukemia; Structure-Activity Relationship; Topoisomerase II Inhi | 1990 |
Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Nucleus; Crithidia; DNA; DNA Topoisomerases, Type II | 1990 |
Treatment of relapsed or refractory acute leukemia: comparison of two different regimens.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpl | 1990 |
Amsacrine [4'-(9-acridinylamino)-methanesulfon-m-anisidide] (m-AMSA) and 5-azacytidine (AZA) for remission reinduction in patients with relapsed adult acute nonlymphocytic leukemia. An ECOG pilot study. Eastern Cooperative Oncology Group.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; | 1987 |
Determination of amsacrine in human nucleated hematopoietic cells.
Topics: Amsacrine; Chromatography, High Pressure Liquid; Dextrans; Hematopoietic System; Humans; Leukemia; L | 1987 |
Topoisomerase II as a target of antileukemic drugs.
Topics: Amsacrine; Animals; DNA Topoisomerases, Type II; Drug Resistance; Humans; Leukemia; Leukemia, Experi | 1987 |
Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human le
Topics: Amsacrine; Cell Division; Cell Nucleus; Cytarabine; DNA; DNA Topoisomerases, Type II; Drug Resistanc | 1987 |
Combined chemotherapy with m-amsacrine in high-risk patients with acute non-lymphocytic leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; E | 1987 |
Prolonged survival after high-dose cytosine arabinoside and amsacrine induction in patients with previously untreated de novo acute nonlymphocytic leukemia.
Topics: Acute Disease; Amsacrine; Bone Marrow Transplantation; Cytarabine; Dose-Response Relationship, Drug; | 1987 |
Sequential pilot studies of intensive postremission chemotherapy for acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Ma | 1987 |
Chemotherapy for relapsed and resistant acute nonlymphoblastic leukemia. Effect of ATA, an amsacrine-containing regime.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; C | 1988 |
Treatment of acute leukaemia with m-AMSA in combination with cytosine arabinoside.
Topics: Aged; Amsacrine; Chemical and Drug Induced Liver Injury; Cytarabine; Female; Gastrointestinal Diseas | 1986 |
Amsacrine treatment of patients with supraventricular arrhythmias and acute leukemia.
Topics: Acute Disease; Aged; Amsacrine; Arrhythmia, Sinus; Atrial Fibrillation; Female; Humans; Leukemia; Mi | 1987 |
Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; | 1987 |
Sensitivity and resistance to chemotherapy in acute leukemia: correlation with in vitro drug uptake and lack of potentiation by verapamil.
Topics: Acute Disease; Adult; Aged; Amsacrine; Cells, Cultured; Doxorubicin; Drug Resistance; Drug Synergism | 1987 |
Combination chemotherapy with diaziquone and amsacrine in relapsed and refractory acute nonlymphocytic leukemia: a Cancer and Leukemia Group B Study.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Agents; Aziridi | 1987 |
The use of amsacrine plus intermediate-dose cytosine arabinoside in relapsed and refractory acute nonlymphocytic leukemia.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukem | 1987 |
Comparison of the pharmacokinetics of AMSA and AMSA-lactate in patients with acute nonlymphoblastic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Female; Humans; Lactates; Lactic Acid; Leukemia; | 1987 |
Acute myocardial necrosis during administration of amsacrine.
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Electrocardiography; Female; Humans; Leukemia; Mid | 1986 |
Phase II study of combination chemotherapy with etoposide and amsacrine in relapsed adult leukemia.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 1986 |
[A new drug and current strategy in the treatment of acute non-lymphocytic leukemia in adults].
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Anthraquinones; Antineoplastic Agents; Cytarabine; | 1986 |
Drug sensitivity and cross-resistance of the 4'-(9-acridinylamino)methanesulfon-m-anisidide-resistant subline of HL-60 human leukemia.
Topics: Aminoacridines; Amsacrine; Cell Line; Cell Survival; Cytarabine; Doxorubicin; Drug Resistance; Etopo | 1986 |
Comparison of in vitro activity of cytotoxic drugs towards human carcinoma and leukaemia cell lines.
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Cell Count; Cell Line; Cell Survival; Colonic Neop | 1986 |
Effect of m-AMSA on the cellular pharmacology of ara-CTP in human leukemic cells during therapy with high-dose ara-C.
Topics: Amsacrine; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Dose-Response Rela | 1986 |
Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; B | 1987 |
Combination amsacrine and high-dose cytosine arabinoside in acute leukemia.
Topics: Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leuke | 1985 |
Amsacrine: a new drug for hematological malignancies.
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Humans; Intercalating Agents; Leukemia; Lymphoma | 1985 |
Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combine | 1985 |
High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase I Pilot Study for the Eastern Cooperative Oncology Group.
Topics: Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; | 1985 |
Treatment of acute leukemia with amsacrine and high-dose cytarabine.
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine | 1985 |
Amsacrine with high-dose cytarabine in acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Combined Chemother | 1985 |
[Experiences with HD-Ara C treatment in leukemia patients].
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine | 1985 |